AI
TCRR

Atom Investors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Atom Investors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-49,634
Closed -$1.01M – 623
2020
Q3 		$1.01M Buy
+49,634
New +$871K 0.1% 192

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Atom Investors's TCRR Position: Q4 2020 in Review

Atom Investors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2020, closing a stake of 49,634 shares — an estimated $1.01M sold.

Atom Investors first reported a position in TCRR in Q3 2020 and held it in 1 quarter. The position peaked at $1.01M in Q3 2020. 118 funds tracked by Wall St. Rank hold TCRR as of Q4 2020.

  • Atom Investors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Atom Investors sold 49,634 TCR2 Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $1.01M.
  • Atom Investors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Atom Investors's TCR2 Therapeutics Inc. Common Stock position peaked at $1.01M in Q3 2020.
  • 118 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2020.

Based on Atom Investors's 13F filing for Q4 2020, filed 16 Feb 2021.